Indian patent filing targets next-generation psychedelics for addiction treatment
Clearmind Medicine (Nasdaq: CMND) Filed a patent application in India on March 27, 2026 for the next generation, non-hallucinogenic neuroplastogen-derived compounds targeting mental health disorders and addiction. The filing, with the Indian Patent Office, expands the company’s global intellectual property portfolio and forms an exclusive worldwide license agreement with Yissumseeking … Read more